Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin

Australas J Dermatol. 2009 Feb;50(1):56-9. doi: 10.1111/j.1440-0960.2008.00506.x.

Abstract

We report a patient with pyoderma gangrenosum successfully treated with intravenous immunoglobulin. He had previously been treated for 4 years with high-dose corticosteroids and had developed insulin-dependent diabetes mellitus. Multiple corticosteroid-sparing agents had failed or were contraindicated. He developed no adverse effects from intravenous immunoglobulin, which allowed reduction of his prednisone to 3 mg/day, and his ulcer has completely healed.

Publication types

  • Case Reports

MeSH terms

  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / complications
  • Drug Therapy, Combination
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Leg Ulcer / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum / drug therapy*
  • Pyoderma Gangrenosum / etiology
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors